DENTSPLY SIRONA Inc. $XRAY Shares Acquired by Fifth Third Bancorp

Fifth Third Bancorp boosted its holdings in DENTSPLY SIRONA Inc. (NASDAQ:XRAY) by 12,357.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 378,718 shares of the medical instruments supplier’s stock after purchasing an additional 375,678 shares during the quarter. Fifth Third Bancorp’s holdings in DENTSPLY SIRONA were worth $4,393,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Eurizon Capital SGR S.p.A. acquired a new stake in shares of DENTSPLY SIRONA during the fourth quarter worth $26,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of DENTSPLY SIRONA in the 1st quarter valued at about $26,000. Caitong International Asset Management Co. Ltd grew its position in shares of DENTSPLY SIRONA by 337.9% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,750 shares of the medical instruments supplier’s stock valued at $35,000 after buying an additional 2,122 shares during the last quarter. Farther Finance Advisors LLC grew its position in shares of DENTSPLY SIRONA by 119.1% during the 4th quarter. Farther Finance Advisors LLC now owns 3,773 shares of the medical instruments supplier’s stock valued at $43,000 after buying an additional 2,051 shares during the last quarter. Finally, Performa Ltd US LLC raised its stake in DENTSPLY SIRONA by 116.1% during the fourth quarter. Performa Ltd US LLC now owns 4,250 shares of the medical instruments supplier’s stock worth $49,000 after acquiring an additional 2,283 shares during the period. Institutional investors own 95.70% of the company’s stock.

Insider Transactions at DENTSPLY SIRONA

In other DENTSPLY SIRONA news, Director Brian T. Gladden bought 9,985 shares of the stock in a transaction that occurred on Monday, June 15th. The shares were purchased at an average cost of $10.02 per share, for a total transaction of $100,049.70. Following the transaction, the director directly owned 61,849 shares in the company, valued at $619,726.98. The trade was a 19.25% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Brian P. Mckeon bought 10,000 shares of the business’s stock in a transaction on Friday, June 12th. The shares were acquired at an average cost of $10.12 per share, for a total transaction of $101,200.00. Following the purchase, the director directly owned 10,000 shares in the company, valued at $101,200. This represents a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders acquired 35,160 shares of company stock worth $351,179. Company insiders own 0.46% of the company’s stock.

DENTSPLY SIRONA Trading Up 1.5%

Shares of NASDAQ:XRAY opened at $14.06 on Friday. The company has a market cap of $2.82 billion, a PE ratio of -4.46, a P/E/G ratio of 1.67 and a beta of 0.89. The company’s 50-day moving average price is $10.81 and its 200 day moving average price is $11.74. DENTSPLY SIRONA Inc. has a fifty-two week low of $9.40 and a fifty-two week high of $17.09. The company has a quick ratio of 0.98, a current ratio of 1.53 and a debt-to-equity ratio of 1.52.

DENTSPLY SIRONA (NASDAQ:XRAY) last posted its earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.27 EPS for the quarter, missing the consensus estimate of $0.28 by ($0.01). DENTSPLY SIRONA had a positive return on equity of 18.83% and a negative net margin of 17.06%.The firm had revenue of $880.00 million during the quarter, compared to the consensus estimate of $841.80 million. During the same quarter last year, the company posted $0.43 EPS. DENTSPLY SIRONA’s revenue for the quarter was up .1% on a year-over-year basis. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Sell-side analysts anticipate that DENTSPLY SIRONA Inc. will post 1.42 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on XRAY shares. Barclays cut their target price on shares of DENTSPLY SIRONA from $12.00 to $9.00 and set an “underweight” rating on the stock in a report on Thursday, June 4th. Citigroup started coverage on DENTSPLY SIRONA in a report on Wednesday, April 15th. They set a “sell” rating and a $10.00 target price for the company. BMO Capital Markets started coverage on DENTSPLY SIRONA in a report on Wednesday, July 8th. They issued a “market perform” rating and a $12.00 price target on the stock. UBS Group reduced their price objective on DENTSPLY SIRONA from $18.00 to $17.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Finally, Mizuho lowered their price objective on DENTSPLY SIRONA from $16.00 to $14.00 and set a “neutral” rating for the company in a research note on Wednesday, May 6th. Three analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $13.42.

DENTSPLY SIRONA Company Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.